Calypte eyes China in drive to market rapid tests for HIV
This article was originally published in Clinica
As part of efforts to commercialise its rapid testing platform for HIV-1/2, Calypte Biomedical has begun a clinical trial of three antibody tests in China, where the number of infections are predicted soar over the coming years.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.